ID   BL-67
AC   CVCL_C156
SY   BL67; BL 67; BL 067; IARC/BL67; IARC/BL 67; IARC-BL67; IARC BL67; IARC BL 67
DR   Cosmic; 931122
DR   Cosmic; 2804862
DR   DSMZ; ACC-921
DR   DSMZCellDive; ACC-921
DR   Wikidata; Q54797238
RX   PubMed=1620543;
RX   PubMed=3004968;
RX   PubMed=3934070;
RX   PubMed=8108117;
RX   PubMed=9473234;
RX   PubMed=11793449;
RX   PubMed=18647998;
CC   From: International Agency of Research on Cancer (IARC); Lyon; France.
CC   Population: Caucasian.
CC   Doubling time: ~10-25 hours (DSMZ=ACC-921).
CC   Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Pro75Ser (c.223C>T); Zygosity=Unspecified (PubMed=8108117).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A1DZ ! BL-78
OI   CVCL_IV27 ! IARC-309
SX   Female
AG   35Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 18
//
RX   PubMed=1620543;
RA   Apel T.W., Mautner J., Polack A., Bornkamm G.-W., Eick D.;
RT   "Two antisense promoters in the immunoglobulin mu-switch region drive
RT   expression of c-myc in the Burkitt's lymphoma cell line BL67.";
RL   Oncogene 7:1267-1271(1992).
//
RX   PubMed=3004968; DOI=10.1002/j.1460-2075.1985.tb04140.x;
RA   Eick D., Piechaczyk M., Henglein B., Blanchard J.-M., Traub B.,
RA   Kofler E., Wiest S., Lenoir G.M., Bornkamm G.-W.;
RT   "Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer
RT   half-lives.";
RL   EMBO J. 4:3717-3725(1985).
//
RX   PubMed=3934070;
RA   Lenoir G.M., Vuillaume M., Bonnardel C.;
RT   "The use of lymphomatous and lymphoblastoid cell lines in the study of
RT   Burkitt's lymphoma.";
RL   IARC Sci. Publ. 60:309-318(1985).
//
RX   PubMed=8108117;
RA   Albert T., Urlbauer B., Kohlhuber F., Hammersen B., Eick D.;
RT   "Ongoing mutations in the N-terminal domain of c-Myc affect
RT   transactivation in Burkitt's lymphoma cell lines.";
RL   Oncogene 9:759-763(1994).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=11793449; DOI=10.1002/gcc.10022;
RA   Sobol H., Benziane A., Kerangueven F., Yin L., Noguchi T., Pauly S.,
RA   Eisinger F., Longy M., Romeo G., Lenoir G.M., Birnbaum D.;
RT   "Genome-wide search for loss of heterozygosity in Burkitt lymphoma
RT   cell lines.";
RL   Genes Chromosomes Cancer 33:217-224(2002).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//